1. A method of aligning antennas of an intra-oral and extra-oral electronic wireless device, comprising the steps of:
recording three-dimensional anatomical data of at least a portion of an oral cavity of a subject utilizing an imaging device;
recording three-dimensional anatomical data of at least a portion of an external ear of the subject utilizing the imaging device;
determining a spatial relationship between a landmark in the oral cavity and a landmark in or near the external ear;
modeling an intra-oral antenna based upon the recorded anatomical data of the oral cavity; and
modeling an extra-oral antenna based upon the recorded anatomical data of the external ear, wherein the intra-oral and extra-oral antennas are configured and oriented relative to each other for optimal signal transmission based upon the recorded anatomical data of the oral cavity and external ear.
2. The method of claim 1, wherein the imaging device is a non-ionizing radiation system.
3. The method of claim 1, wherein the imaging device is selected from the group consisting of an X-ray imaging system, a computed tomography imaging system, a magnetic resonance imaging system, and an optical imaging system.
4. The method of claim 1, comprising the further steps of:
constructing an internal unit configured to be disposed within the oral cavity of the subject, the intra-oral antenna coupled to the internal unit; and
constructing an external unit configured to be disposed within or proximate to the ear of the subject, the extra-oral antenna coupled to the external unit.
5. The method of claim 4, wherein the intra-oral and extra-oral antennas are fixedly and spatially oriented relative to each other for optimal gain and polarization when the internal and external units are disposed within or upon the subject.
6. The method of claim 1, wherein the intra-oral antenna has a first angular orientation, and the extra-oral antenna has a second angular orientation relative to the first angular orientation, wherein the signal transmission is optimized when the intra-oral and extra-oral antennas are orientated in the first and second angular orientations, respectively.
7. The method of claim 1, wherein the imaging device is an ionizing radiation system.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of formula
or a pharmaceutically acceptable salt thereof or a prodrug thereof wherein
R1 to R10 are each independently selected from hydrogen or a straight or branched alkyl of from 1 to 6 carbons, benzyl, or phenyl;
m is an integer of from 0 to 3;
n is an integer of from 1 to 2;
o is an integer of from 0 to 3;
p is an integer of from 1 to 2;
q is an integer of from 0 to 2;
r is an integer of from 1 to 2;
s is an integer of from 1 to 3;
t is an integer of from 0 to 2; and
u is an integer of from 0 to 1.
2. A compound according to claim 1 of Formula I.
3. A compound according to claim 1 of Formula I wherein
R1 to R10 is hydrogen;
m is of from 0 to 3; and
n is 1 or 2.
4. A compound according to claim 1 selected from:
(\xb1)-2-Aza-spiro3.5nonane-1-carboxylic acid hydrochloride;
(\xb1)-2-Aza-spiro4.5decane-4-carboxylic acid hydrochloride;
(R)-2-Aza-spiro4.5decane-4-carboxylic acid hydrochloride;
(S)-2-Aza-spiro4.5decane-4-carboxylic acid hydrochloride; and
(R)-2-Aza-spiro4.5decane-4-carboxylic acid.
5. A compound according to claim 1 of Formula II.
6. A compound according to claim 1 of Formula II wherein
R1 to R10 is hydrogen,
o is from 0 to 3; and
p is 1 to 2.
7. A compound according to claim 1 of Formula III wherein
R1 to R10 is hydrogen,
q is from 0 to 2; and
r is 1 to 2.
8. A compound according to claim 1 of Formula III wherein:
(+)-3aS-(3\u03b1,7a\u03b1)-(Octahydro-isoindol-3a-yl)-acetic acid trifluoroacetate.
9. A compound according to claim 1 and selected from:
7-Methyl-2-aza-spiro4.4nonane-4-carboxylic acid;
4\u03b1,5\u03b2(R*)7-Methyl-2-aza-spiro4.5decane-4-carboxylic acid;
4\u03b1,5\u03b1(S*)7-Methyl-2-aza-spiro4.5decane-4-carboxylic acid;
4\u03b1,5\u03b1(R*)7-Methyl-2-aza-spiro4.5decane-4-carboxylic acid;
4\u03b1,5\u03b2(S*)7-Methyl-2-aza-spiro4.5decane-4-carboxylic acid;
7,8-Dimethyl-2-aza-spiro4.4nonane-4-carboxylic acid;
7-Methyl-2-aza-spiro4.5decane-4-carboxylic acid;
7,9-Dimethyl-2-aza-spiro4.5decane-4-carboxylic acid;
Spirobicyclo3.3.1nonane-9,3\u2032-pyrrolidine-4\u2032-carboxylic acid;
Spiropyrrolidine-3,2\u2032-tricyclo3.3.1.13,7decane-4-carboxylic acid;
3-Amino-6-methyl-spiro3.5nonane-1-carboxylic acid;
3-Amino-6,8-dimethyl-spiro3.5nonane-1-carboxylic acid;
4-Amino-7-methyl-spiro4.5decane-1-carboxylic acid;
4-Amino-7,9-dimethyl-spiro4.5decane-1-carboxylic acid;
3-Amino-6-methyl-spiro3.4octane-1-carboxylic acid;
3-Amino-6,7-dimethyl-spiro3.4octane-1-carboxylic acid;
4-Amino-7-methyl-spiro4.4nonane-1-carboxylic acid; and
4-Amino-7,8-dimethyl-spiro4.4nonane-1-carboxylic acid.
10. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.
11. A method for treating epilepsy comprising administering a therapeutically effective amount of a compound according to claim 1 to a mammal in need of said treatment.
12. A method for treating faintness attacks, hypokinesia, and cranial disorders comprising administering a therapeutically effective amount of a compound according to claim 1 to a mammal in need of said treatment.
13. A method for treating neurodegenerative disorders comprising administering a therapeutically effective amount of a compound according to claim 1 to a mammal in need of said treatment.
14. A method for treating depression comprising administering a therapeutically effective amount of a compound according to claim 1 to a mammal in need of said treatment.
15. A method for treating anxiety comprising administering a therapeutically effective amount of a compound according to claim 1 to a mammal in need of said treatment.
16. A method for treating panic comprising administering a therapeutically effective amount of a compound according to claim 1 to a mammal in need of said treatment.
17. A method for treating pain comprising administering a therapeutically effective amount of a compound according to claim 1 to a mammal in need of said treatment.
18. A method for treating neuropathological disorders comprising administering a therapeutically effective amount of a compound according to claim 1 to a mammal in need of said treatment.
19. A compound selected from:
2-Benzyl-2-aza-spiro4.5decane-4,4-dicarboxylic acid dimethyl ester hydrochloride;
2-Aza-spiro4.5decane-4,4-dicarboxylic acid dimethyl ester hydrochloride;
1-Benzyloxymethyl-2-aza-spiro3.5nonane-2-carboxylic acid tert-butyl ester;
1-Hydroxymethyl-2-aza-spiro3.5nonane-2-carboxylic acid tert-butyl ester;
2-Aza-spiro3.5nonane-1,2-dicarboxylic acid 2-tert-butyl ester;
3aS-(3\u03b17a\u03b1)-7a-tert-Butoxycarbonylmethyl-1-oxo-octahydro-isoindole-2-carboxylic acid tert-butyl ester; and
3aS-(\u03b17a\u03b1)-3a-tert-Butoxycarbonylmethyl-octahydro-isoindole-2-carboxylic acid tert-butyl ester.